CONDYVAC. Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516098-62-00

Acronym

P150957

Enrollment

300

Registered

2024-12-10

Start date

2018-01-11

Completion date

2025-11-04

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

External Genital Warts (EGW)

Brief summary

Relapse-free “survival”. Relapse will have to be clinically confirmed.

Detailed description

Percentage of patients with local and/or systemic reactions during the study

Interventions

DRUGGardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant

DRUGadsorbed)

DRUGGardasil

DRUGsuspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6

DRUG11

DRUG16

DRUG18] (Recombinant

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relapse-free “survival”. Relapse will have to be clinically confirmed.	—

Secondary

Measure	Time frame
Percentage of patients with local and/or systemic reactions during the study	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026